HYPERRHO S/D FULL DOSE Rx
Generic Name and Formulations:
Rho(D) immune globulin human 1500 IU; per syringe; soln for IM inj; preservative-free; latex-free.
Grifols Biologicals, Inc.
Indications for HYPERRHO S/D FULL DOSE:
Prevention of isoimmunization in non-sensitized Rho(D) negative women during pregnancy and in appropriate obstetrical conditions, unless the fetus or father is known to be Rho(D) negative. Prevention of isoimmunization in Rho(D) negative individuals transfused with Rho(D) positive blood products.
See literature. Give IM only. Pregnancy (28 weeks gestation), postpartum prophylaxis (within 72 hours), obstetric complications, invasive procedures during pregnancy: 1500IU. Incompatible transfusions (within 72 hours): volume of red blood cells transfused divided by 15mL provides the number of syringes to be administered; if the dose is a fraction, round to next higher whole number of syringes.
Contains human plasma; monitor for possible infection transmission. IgA deficiency. Pregnancy (Cat.C).
Avoid live vaccines within 3 months.
Local or infusion reactions.
Report all infections suspected to be transmitted by HyperRHO S/D to (800) 520-2807.
Full dose (Single-dose prefilled syringe)—1; Mini dose (Single-dose prefilled syringe)—10
Clinical Pain Advisor Articles
- Analyzing Coverage of Nonpharmacologic Treatments for Low Back Pain
- Smartphone App Helps Evaluate Catastrophizing in Chronic Pain
- Predicting the Magnitude of Placebo Analgesia in Chronic Pain
- Dsuvia Gains FDA Approval: We Want to Hear Your Thoughts
- Operant Learning May Provide More Benefits Than Energy Conservation in Fibromyalgia
- The Unintended Consequences of the CDC Opioid Guideline According to Pain Management Specialists
- Seven-Item Pain Intensity Measure Reliable in Individuals With Dementia
- Initial Consultation for Neck Pain May Reduce Opioid Consumption, Healthcare Utilization
- FDA-Approved Test Provides Pharmacogenetic Reports Directly to Consumers
- Set of Interventions May Effectively Reduce Opioid Overprescribing
- Methamphetamine Use on the Rise in Patients With Opioid Use Disorder
- Two Screening Tools May Accurately Predict Transition From Acute to Chronic Low Back Pain
- Dozens of Medical Groups Join Forces to Improve Diagnoses
- FDA Grants Non-Opioid Analgesic VVZ-149 Fast Track Status
- Little to No Association Found Between Physician Performance and Medical School Ranking